(ATN) Guidelines for Clinical Management Using Plasma HIV RNA Quantitation

(ATN) Guidelines for Clinical Management Using Plasma HIV RNA Quantitation

AIDS TREATMENT NEWS #233, October 20, 1995
John S. James

[Note: The following are the initial guidelines for using viral load, which are being provided to physicians in the CPCRA 036 study described above. These guidelines will be reviewed periodically throughout the study, and will be changed as new information becomes available.]

The goal of utilizing plasma HIV RNA quantitation in patient management is to keep viral burden AS LOW AS POSSIBLE FOR AS LONG AS POSSIBLE. At present, there are no clear thresholds for "high" or "low" HIV RNA viral burden. The following points represent the state of the art in this area:

* Levels of <10,000 copies (10 Keq/ml) are associated with LOW risk of progression (Mellors J. and others. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. ANNALS OF INTERNAL MEDICINE. 1995; volume 122, pages 573- 579.)

* Levels of >100,000 copies (100 Keq/ml) are associated with HIGH risk of progression (Mellors and others, reference cited).

* The observed biologic variability of the HIV RNA assays may be as high as threefold. Therefore, a change of more than threefold is considered significant, and a change of less than threefold may be due to assay variability. (Todd J. and others. Quantitation of human immunodeficiency virus plasma RNA by branched DNA and reverse transcription coupled polymerase chain reaction assay methods: A critical evaluation of accuracy and reproducibility. SERODIAG. IMMUNOTHER. INFECT. DIS. 1994; volume 6, number 4, pages 233- 239.

* Pachl C. and others. Rapid and precise quantification of HIV-1 RNA in plasma using branched DNA signal amplification assay. JOURNAL OF APPLIED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 1995; volume 8, pages 445- 454.

* D. Chernoff, personal communication, 1995.)

* Repeating the assay improves reliability. It is recommended that the assay be repeated, rather than relying on a single value, before the value is used for decisionmaking to initiate or change therapy. (Todd and others, reference cited.

* Dewar R.L. and others. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. JOURNAL OF INFECTIOUS DISEASES 1994; volume 170, pages 1172-1179. * Pachl and others, reference cited.)

* Changes in plasma HIV RNA are seen as early as two to four weeks after the initiation of a new therapy with antiviral activity. Obtaining a plasma HIV RNA quantitation at this time may indicate whether the therapy has been effective in acutely decreasing plasma HIV RNA.

* Obtaining HIV RNA measurements during any acute intercurrent illness or within four weeks after a patient receives a vaccination (including influenza) may impact on the interpretation of plasma HIV RNA results.

951020
ATN23302

Copyright © 1995 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .